card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Validation of a Stem Cell Assay Used as a Key Efficacy Marker for FDA Approval

Home / Insights / Validation of a Stem Cell Assay Used as a Key Efficacy Marker for FDA Approval

Presented at CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry, May 5-8, 2024

 

The recent announcement by BiolineRx of the FDA approval of APHEXDA™ (motixafortide), represents the first development in stem cell mobilization for the treatment of multiple myeloma to be approved in the U.S. in a decade.  Flow cytometry data generated at IQVIA Laboratories was fundamental to FDA approval, confirming that the apheresis CD34+ stem cell collection goal of ≥ 6 × 106 CD34+ cells/kg had been reached.. The randomized Phase 3 study was run across five countries in USA and Europe, requiring a robust, globally harmonized stem cell assay to assess efficacy results.

 

This scientific poster details the results of validation, technology transfer, and QC performance during clinical testing, and includes the production of critical efficacy data.

 

Authors:  
IQVIA Laboratories – Karen Smith, Megan McCausland, Alistair Watt
BioLineRx Ltd. Modi'in, Israel – Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Debby Ickowicz, Liron Shemesh- Darvish

 

Complete the form below to access this scientific poster.